IgCLL group activities in 2009 and beyond. Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece

Similar documents
Biomarkers in Chronic Lymphocytic Leukemia: the art of synthesis. CLL Immunogenetics. Overview. Anastasia Chatzidimitriou

Partial versus Productive Immunoglobulin Heavy Locus Rearrangements in Chronic Lymphocytic Leukemia: Implications for B-Cell Receptor Stereotypy

The 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010

Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing

39 th General Assembly of ERIC members. Sunday, 6 th of December 2015 (Orlando, Florida)

Chromosome Banding Analysis in CLL Panagiotis Baliakas, MD-PhD

SIMPOSIO - Leucemia Linfatica Cronica: presente e futuro nella gestione del paziente refrattario

Update on the ERIC TP53 Network Activities and TP53 Certification Overview and Results of Round 4

Supplemental data. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic. leukemia

NGS IMMUNOGENETICS IN CLL RESEARCH. Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH

CLL Ireland Information Day Presentation

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Immunoglobulin light chain repertoire in chronic lymphocytic leukemia

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients

Update on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry

CLL Sample! Clinical Trials! Accrual, tracking,! correlative studies! Immunophenotyping! Surface & intracellular! ZAP-70/CD38! prognosis!

ERIC TP53 Network activities and outcomes. Sarka Pospisilova

BIOGRAPHICAL SKETCH. DEGREE (if applicable)

Submitted to Leukemia as a Letter to the Editor, May Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69.

New Prognostic Markers in CLL

Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia

Stereotyped B Cell Receptors in Chronic Lymphocytic Leukaemia

Prevalence of BTK and PLCγ2 Mutations in Patients relapsing under Ibrutinib. Lydia Scarfò Silvia Bonfiglio Lesley Ann Sutton

TP53 Certification overview and results of round 3

Cross Border Genetic Testing for Rare Diseases

MBL in Blood Donors: An Extended Immunophenotypic Analysis of CLL-like, CD5+ MBL.

Reporting TP53 gene analysis results in CLL

BIOGRAPHICAL SKETCH NAME: ANASTASIA CHATZIDIMITRIOU POSITION TITLE: SENIOR RESEARCHER

BASIC PROCEDURES SAMPLING, MATERIAL, SANGER SEQUENCING

B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia. Abstract

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

THE BENEFITS AND CHALLENGES OF PERFORMING A CENTRAL REVIEW OF RESPONSE IN A CHRONIC LYMPHOCYTIC LEUKAEMIA TRIAL

real-time AQ data 2007 and plans for 2008

Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia

Short Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia

3rd Meeting of the European Research Initiative on CLL (ERIC) during the 10th Meeting of the International Working Group on CLL (IWCLL)

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

9 th Annual Symposium of the European LeukemiaNet. 13 th Annual Symposium of the German Competence Network Acute and chronic Leukemias.

WCPT COUNTRY PROFILE December 2017 SERBIA

Smokefree Policies in Europe: Are we there yet?

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 HUNGARY

Immunoglobulin Gene Repertoire in Chronic Lymphocytic Leukemia: Insight into Antigen Selection and Microenvironmental Interactions

Weekly Influenza Surveillance Report. Week 11

An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV Receptors

Overview of drug-induced deaths in Europe - What does the data tell us?

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

The Human T Cell Receptor Alpha Variable (TRAV) Genes

Chronic lymphocytic leukemia is eradication feasible and worthwhile?

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

CLL: MRD as a Surrogate Endpoint for Clinical Trials White Oak February 27, Chronic Lymphocytic Leukemia. Paolo Ghia

Prognostic markers and DNA methylation profiling in lymphoid malignancies

Overview of European Consumption Databases

The health economic landscape of cancer in Europe

NOTCH1 mutations in CLL associated with trisomy 12

European Status report on Alcohol and Health

1. What to test. 2. When to test

Real Life, Real PD Survey

The Human T cell Receptor Beta Variable (TRBV) Genes

The Teleostei Immunoglobulin Heavy IGH Genes

Analysis of CD38 and ZAP70 mrna expression among cytogenetic subgroups of Iranian chronic-lymphocytic-leukemia patients

LEBANON. WCPT COUNTRY PROFILE December 2018

Nicholas Chiorazzi The Feinstein Ins3tute for Medical Research Northwell Health Manhasset, NY

The Human T Cell Receptor Alpha Joining (TRAJ) Genes

DENMARK. WCPT COUNTRY PROFILE December 2018

GERMANY. WCPT COUNTRY PROFILE December 2018

Developing indicators on Open Access by combining evidence from diverse data sources

EUVAC.NET A surveillance network for vaccine-preventable diseases

The Identification of Food Safety Priorities using the Delphi Technique

MED B Form CLL. Johannes Schetelig. London 09/April/

CLL Complete SM Report

Engagement in language assessment / Regions of Europe

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

Priv.Doz. Dr. Ulrich Wedding Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany SIOG CLL TASKFORCE

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

Current dietary habits in Europe far from plant based eating

clinical practice guidelines

Calreticulin as a novel B cell receptor antigen in chronic lymphocytic leukemia

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

REVIEW OF THE ANALYSIS RELATED TO RABIES DIAGNOSIS AND FOLLOW-UP OF ORAL VACCINATION PERFORMED IN NRLS IN 2015

Advances in the treatment of Chronic Lymphocytic Leukemia

Where we stand in EFORT

European Collaboration on Dementia. Luxembourg, 13 December 2006

Outcome of proficiency test on EIA serology

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

Published Ahead of Print on July 12, 2011, as doi: /haematol Copyright 2011 Ferrata Storti Foundation.

Jan Philippé. VAKB 3 februari 2014

Access to treatment and disease burden

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

EFSA s Concise European food consumption database. Davide Arcella Data Collection and Exposure Unit

Transcription:

IgCLL group activities in 2009 and beyond Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece

Troubleshooting Standardization

Standardization and Validation

Standardization and Validation Immunoglobulin gene mutational status

TROUBLE IG SEQUENCES IGHV-(IGHD)-IGHJ recombination Rearrangements carrying non functional genes Problematic IGHV-IGHD-IGHJ junctions Somatic Hypermutation Stop codons Absence of CDR3 anchors Insertion / Deletions

Database of trouble sequences collected since February 2007 Over 80 trouble sequences have been submitted to the review board for analysis in 2.5 years (an average of 30 per year). 1. Borderline mutated case 2. Missing HCDR3 landmarks 3. Truncated IGHV sequences 4. Insertions and deletions 5. No IGHV sequence 6. Double productive 7. Double productive with discordant mutational status 8. Single unproductive 9. Intraclonal diversity

Database of trouble sequences collected since February 2007 Over 80 trouble sequences have been submitted to the review board for analysis in 2.5 years (an average of 30 per year). 1. Borderline mutated case 2. Missing HCDR3 landmarks 3. Truncated IGHV sequences 4. Insertions and deletions 5. No IGHV sequence 6. Double productive 7. Double productive with discordant mutational status 8. Single unproductive 9. Intraclonal diversity

Significance of trouble sequences Analysis of trouble sequences provides: An opportunity to investigate clinical correlations. An opportunity to decipher the molecular mechanisms that were used to generate the IG sequences. This information can be applied to normal B cells as well as the CLL B cells.

New analytical tools

bioinformatics analysis team CERTH REFINEMENT OF ANALYTICAL TOOLS IMGT, Montpellier Marie-Paule Lefranc Veronique Giudicelli Xavier Brochet BAT, CERTH, Thessaloniki Nikos Darzentas Anastasia Hadzidimitriou Andreas Agathagelidis

Insertions/Duplications Deletions Frequency in CLL: ~3% An analytical nightmare (until recently ) Belessi et al. Eur J Immunol. 2006;36:1963-74.

A paradigmatic example of bioinformatics advances meeting clinical needs!

Upcoming developments in 2010 IMGT V-QUEST Alerts Sequence ambiguities or troubles Short sequences leading to gene assignment problems Identification of IGHC genes Analysis of incomplete IGHD-J rearrangements Biological significance (Tsakou et al. ASH 2009) Practical significance: MRD testing

EDUCATION

3 rd Educational Workshop Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia 24-25 September 2009 Thessaloniki - Greece

Sponsorship/support:

60 participants, 17 countries Austria 2 Belgium 2 Czech Republic 2 Denmark 4 Germany 1 Greece 17 Iran 1 Ireland 1 Italy 8 Netherlands 3 Poland 2 Romania 1 Serbia 1 Spain 4 Sweden 8 UK 2 US 1

Workshop activities and innovations Questionnaire: current everyday practice throughout Europe Material, PCR methodology, Interpretation of PCR results, Sequencing, Reporting to the clinic Exercises and web-based assessment and self-assessment Light chain analysis

Next Workshop Italy 2011

Publications

The first book!

A new book! (in preparation)! Biological prognostic markers in CLL

Biological prognostic markers in CLL Stamatopoulos, Ghia, Rosenquist, eds. Foreword Section I - Clinico-biological background of CLL CLL biology Clinical prognostic markers (Rai/Binet staging, serum markers) Section II - Cytogenetics/molecular cytogenetics Genomic aberrations p53 dysfunction Section III - Immunoglobulin genes IGHV gene mutation status as prognostic marker Stereotyped B-cell receptors in CLL Section IV - Immunophenotyping CD38 onwards: the evolution of flow cytometric markers in CLL ZAP-70 From MBL to MRD: to the limits of flow cytometry Section V RNA-based methods/micro-rna RNA-based molecular markers Micro-RNA in CLL Section IV Clinical application of new prognostic markers Clinical application of new prognostic markers Conclusions Emili Montserrat, Michael Keating Nicholas Chiorazzi, Federico Caligaris-Cappio Kanti Rai, Eva Kimby Stephan Stilgenbauer, Hartmut Doehner Andrew Pettit, Sarka Pospisilova Paolo Ghia, Richard Rosenquist Chrysoula Belessi, Kostas Stamatopoulos Rajendra Damle, Silvia Deaglio Florence Cymbalista, Francesc Bosch Andy Rawstron, Paolo Ghia Frederic Davi, Anne-Mette Buhl George Adrian Calin, Carlo Croce David Oscier, Michael Hallek Daniel Catovsky, Tom Kipps Sponsored in part by Roche Hellas Wolters Kluwer - Lippincott

San Raffaele, Milano Paolo Ghia Uppsala University Richard Rosenquist Pitié Salpêtrière, Paris Fred Davi Nikea Hospital, Athens Chrysoula Belessi Tenovus Lab, Southampton Kathy Potter Erasmus University, Rotterdam Ton Langerak